» Articles » PMID: 34522251

Coordinated Medical Care for Children with Neurofibromatosis Type 1 and Related RASopathies in Poland

Overview
Journal Arch Med Sci
Specialty General Medicine
Date 2021 Sep 15
PMID 34522251
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Coordinated medical care offered in Poland for patients suffering from neurofibromatosis type 1 and related RASopathies combines complex multispecialty consultation with permanent supervision and the patient's oriented longitudinal care. Neurofibromatosis type 1 is one of the most common single gene disorders in the global population, observed in 1 out of 2500-3000 live births. It is a primary neoplasia disease with 100% penetration of the gene mutation but remarkable age-dependent onset of different disease signs and symptoms, outstanding clinical heterogeneity between patients even in one family and lack of genotype-phenotype correlation, a high rate of spontaneous mutation exceeding 50%, and multiple comorbidities among which increased risk of malignancy is the most important. Medical practice proved that not only patient-oriented complex but also coordinated care provided in centers of competence is indispensable for patients and the families and provides a sense of medical security to them in conjunction with public health costs rationalization.

Citing Articles

Mammographic breast density and IGF-1 gene polymorphisms rs1520220, rs2946834 and rs6219 in Polish women.

Smolarz B, Polac I, Romanowicz H Contemp Oncol (Pozn). 2021; 25(3):191-197.

PMID: 34729039 PMC: 8547182. DOI: 10.5114/wo.2021.109727.


Breast cancer risk (un)awareness among women suffering from neurofibromatosis type 1 in Poland.

Karwacki M Contemp Oncol (Pozn). 2020; 24(2):140-144.

PMID: 32774141 PMC: 7403769. DOI: 10.5114/wo.2020.97637.

References
1.
Torres Nupan M, Velez Van Meerbeke A, Lopez Cabra C, Herrera Gomez P . Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1. Front Pediatr. 2017; 5:227. PMC: 5670111. DOI: 10.3389/fped.2017.00227. View

2.
Dombi E, Baldwin A, Marcus L, Fisher M, Weiss B, Kim A . Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016; 375(26):2550-2560. PMC: 5508592. DOI: 10.1056/NEJMoa1605943. View

3.
Schrijvers G . Disease management: a proposal for a new definition. Int J Integr Care. 2009; 9:e06. PMC: 2663707. DOI: 10.5334/ijic.301. View

4.
Falzon K, Drimtzias E, Picton S, Simmons I . Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort. Br J Ophthalmol. 2018; 102(10):1367-1371. DOI: 10.1136/bjophthalmol-2017-311305. View

5.
Hirbe A, Gutmann D . Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014; 13(8):834-43. DOI: 10.1016/S1474-4422(14)70063-8. View